Recurrence/regrowth in grade i meningioma: how to predict?

Detalhes bibliográficos
Autor(a) principal: Gervásio Teles Cardoso Decarvalho
Data de Publicação: 2020
Outros Autores: Warley Carvalho da Silva-martins, Kênia Cristina Soares Fonseca de Magalhães, Cristiana Buzelin Nunes, Aleida Nazareth Soares, Luciene Simões de Assis Tafuri, Renata Toscano Simões
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UFMG
Texto Completo: http://hdl.handle.net/1843/41138
Resumo: The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (p = 0.486), but was significantly correlated with peritumoral edema (p = 0.031) and intratumoral calcifications (p = 0.018). Recurrent meningiomas were observed in 14.6% of cases. Immunostaining for each marker was: HLA-G 100%; HLA-E 95.6%; PR 62%; ER 2.1%; AR 6.5%; p53 92.6%; COX-2 100%; HER2 0%; Ki67, mean 2.61 ± 2.29%, median 2.1%. Primary and recurrent meningiomas showed no significant relation with HLA-E and hormone receptors (p > 0.05), except for Ki67, where a higher median was observed in recurrent tumors than in primary (p = 0.014). The larger the tumor, the more severe the peritumoral edema, and the greater the presence of calcifications. Ki67 appears to be a good biomarker of recurrence/regrowth in grade I meningiomas.
id UFMG_6d62f15e00f9caa86a9e2c9e8a11f3e9
oai_identifier_str oai:repositorio.ufmg.br:1843/41138
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling 2022-04-25T17:31:06Z2022-04-25T17:31:06Z20201001144011440114410.3389/fonc.2020.011442234943Xhttp://hdl.handle.net/1843/411380000-0002-5266-6870The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (p = 0.486), but was significantly correlated with peritumoral edema (p = 0.031) and intratumoral calcifications (p = 0.018). Recurrent meningiomas were observed in 14.6% of cases. Immunostaining for each marker was: HLA-G 100%; HLA-E 95.6%; PR 62%; ER 2.1%; AR 6.5%; p53 92.6%; COX-2 100%; HER2 0%; Ki67, mean 2.61 ± 2.29%, median 2.1%. Primary and recurrent meningiomas showed no significant relation with HLA-E and hormone receptors (p > 0.05), except for Ki67, where a higher median was observed in recurrent tumors than in primary (p = 0.014). The larger the tumor, the more severe the peritumoral edema, and the greater the presence of calcifications. Ki67 appears to be a good biomarker of recurrence/regrowth in grade I meningiomas.As moléculas HLA-G e HLA-E, Ki67, progesterona (PR), estrogênio (ER) e receptores androgênicos (AR), p53, COX-2 e HER2 foram estudados para avaliar se o comportamento biológico dos meningiomas grau I está relacionado à sua expressão. Amostras de tecido de 96 pacientes com meningiomas intracranianos grau I foram analisadas por imuno-histoquímica em blocos de microarranjo de tecidos (TMA) usando anticorpos específicos para HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2 e HER2. Os meningiomas foram classificados como pequenos (≤2 cm, 1,0%), médios (>2 e ≤4 cm, 32,3%) e grandes (>4 cm, 66,7%). O tamanho do tumor não foi relacionado à recorrência/recrescimento ( p = 0,486), mas foi significativamente correlacionado com edema peritumoral ( p = 0,031) e calcificações intratumorais ( p= 0,018). Meningiomas recorrentes foram observados em 14,6% dos casos. A imunocoloração para cada marcador foi: HLA-G 100%; HLA-E 95,6%; RP 62%; RE 2,1%; AR 6,5%; p53 92,6%; COX-2 100%; HER2 0%; Ki67, média 2,61 ± 2,29%, mediana 2,1%. Meningiomas primários e recorrentes não apresentaram relação significativa com HLA-E e receptores hormonais ( p > 0,05), exceto para Ki67, onde foi observada mediana maior nos tumores recorrentes do que nos primários ( p = 0,014). Quanto maior o tumor, mais grave o edema peritumoral e maior a presença de calcificações. Ki67 parece ser um bom biomarcador de recorrência/recrescimento em meningiomas grau I.porUniversidade Federal de Minas GeraisUFMGBrasilMED - DEPARTAMENTO DE ANATOMIA PATOLÓGICA E MEDICINA LEGALFrontiers in oncologyMeningiomaMedicinaBiomarkersImmunomarkersHormonal receptorsInflammatory biomarkersHLA-GHLA-EMIB-1Recurrence/regrowth in grade i meningioma: how to predict?Recorrência/recrescimento em meningioma grau I: como prever?info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438949/pdf/fonc-10-01144.pdfGervásio Teles Cardoso DecarvalhoWarley Carvalho da Silva-martinsKênia Cristina Soares Fonseca de MagalhãesCristiana Buzelin NunesAleida Nazareth SoaresLuciene Simões de Assis TafuriRenata Toscano Simõesapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/41138/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALRecorrência, Recrescimento em Meningioma de Grau I.pdfRecorrência, Recrescimento em Meningioma de Grau I.pdfapplication/pdf806729https://repositorio.ufmg.br/bitstream/1843/41138/2/Recorr%c3%aancia%2c%20Recrescimento%20em%20Meningioma%20de%20Grau%20I.pdff979bbb427e9034cf62f17cd9ccfb21eMD521843/411382022-04-25 14:31:06.587oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2022-04-25T17:31:06Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.pt_BR.fl_str_mv Recurrence/regrowth in grade i meningioma: how to predict?
dc.title.alternative.pt_BR.fl_str_mv Recorrência/recrescimento em meningioma grau I: como prever?
title Recurrence/regrowth in grade i meningioma: how to predict?
spellingShingle Recurrence/regrowth in grade i meningioma: how to predict?
Gervásio Teles Cardoso Decarvalho
Immunomarkers
Hormonal receptors
Inflammatory biomarkers
HLA-G
HLA-E
MIB-1
Meningioma
Medicina
Biomarkers
title_short Recurrence/regrowth in grade i meningioma: how to predict?
title_full Recurrence/regrowth in grade i meningioma: how to predict?
title_fullStr Recurrence/regrowth in grade i meningioma: how to predict?
title_full_unstemmed Recurrence/regrowth in grade i meningioma: how to predict?
title_sort Recurrence/regrowth in grade i meningioma: how to predict?
author Gervásio Teles Cardoso Decarvalho
author_facet Gervásio Teles Cardoso Decarvalho
Warley Carvalho da Silva-martins
Kênia Cristina Soares Fonseca de Magalhães
Cristiana Buzelin Nunes
Aleida Nazareth Soares
Luciene Simões de Assis Tafuri
Renata Toscano Simões
author_role author
author2 Warley Carvalho da Silva-martins
Kênia Cristina Soares Fonseca de Magalhães
Cristiana Buzelin Nunes
Aleida Nazareth Soares
Luciene Simões de Assis Tafuri
Renata Toscano Simões
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gervásio Teles Cardoso Decarvalho
Warley Carvalho da Silva-martins
Kênia Cristina Soares Fonseca de Magalhães
Cristiana Buzelin Nunes
Aleida Nazareth Soares
Luciene Simões de Assis Tafuri
Renata Toscano Simões
dc.subject.por.fl_str_mv Immunomarkers
Hormonal receptors
Inflammatory biomarkers
HLA-G
HLA-E
MIB-1
topic Immunomarkers
Hormonal receptors
Inflammatory biomarkers
HLA-G
HLA-E
MIB-1
Meningioma
Medicina
Biomarkers
dc.subject.other.pt_BR.fl_str_mv Meningioma
Medicina
Biomarkers
description The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (p = 0.486), but was significantly correlated with peritumoral edema (p = 0.031) and intratumoral calcifications (p = 0.018). Recurrent meningiomas were observed in 14.6% of cases. Immunostaining for each marker was: HLA-G 100%; HLA-E 95.6%; PR 62%; ER 2.1%; AR 6.5%; p53 92.6%; COX-2 100%; HER2 0%; Ki67, mean 2.61 ± 2.29%, median 2.1%. Primary and recurrent meningiomas showed no significant relation with HLA-E and hormone receptors (p > 0.05), except for Ki67, where a higher median was observed in recurrent tumors than in primary (p = 0.014). The larger the tumor, the more severe the peritumoral edema, and the greater the presence of calcifications. Ki67 appears to be a good biomarker of recurrence/regrowth in grade I meningiomas.
publishDate 2020
dc.date.issued.fl_str_mv 2020
dc.date.accessioned.fl_str_mv 2022-04-25T17:31:06Z
dc.date.available.fl_str_mv 2022-04-25T17:31:06Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1843/41138
dc.identifier.doi.pt_BR.fl_str_mv 10.3389/fonc.2020.01144
dc.identifier.issn.pt_BR.fl_str_mv 2234943X
dc.identifier.orcid.pt_BR.fl_str_mv 0000-0002-5266-6870
identifier_str_mv 10.3389/fonc.2020.01144
2234943X
0000-0002-5266-6870
url http://hdl.handle.net/1843/41138
dc.language.iso.fl_str_mv por
language por
dc.relation.ispartof.pt_BR.fl_str_mv Frontiers in oncology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.publisher.initials.fl_str_mv UFMG
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv MED - DEPARTAMENTO DE ANATOMIA PATOLÓGICA E MEDICINA LEGAL
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
bitstream.url.fl_str_mv https://repositorio.ufmg.br/bitstream/1843/41138/1/License.txt
https://repositorio.ufmg.br/bitstream/1843/41138/2/Recorr%c3%aancia%2c%20Recrescimento%20em%20Meningioma%20de%20Grau%20I.pdf
bitstream.checksum.fl_str_mv fa505098d172de0bc8864fc1287ffe22
f979bbb427e9034cf62f17cd9ccfb21e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv
_version_ 1803589232884711424